Potential of N-aryl(benzyl,heteryl)-2-(tetrazolo[1,5-c]quinazolin-5-ylthio)acetamides as anticancer and antimicrobial agents
Authors:
- Oleksii M. AntypenkoOleksii M. Antypenko
- Lyudmyla M. AntypenkoLALyudmyla M. Antypenko
- Sergiy I. KovalenkoSKSergiy I. Kovalenko
- Andrey M. KatsevAKAndrey M. Katsev
- Olena M. AchkasovaOAOlena M. Achkasova
Open Access
- 1 November 2016
- journal article
- Published by Scientific Scholar in Arabian Journal of Chemistry
- Vol. 9 (6) , 792-805
Abstract
The death rate from cancer and infectious diseases is still very high, therefore research in this area is extremely important and promising as in medical, so in economic point of view. Thus, potassium salt of tetrazolo[1,5-c]quinazolin-5-thion was modified per alkylation by N-aryl(benzyl,heteryl)acetamides with proper confirmation of newly synthesized compounds’ structures by FT-IR, LC–MS, 1H NMR and elemental analysis data. The substances were tested for bioluminescence inhibition against Photobacterium leiognathi Sh1 (5–50μg/mL) to check their cytotoxicity. Then they were screened for antibacterial and antifungal activities (100μg) against Escherichia coli, Staphylococcus aureus, Enterobacter aerogenes and Enterococcus faecalis, Pseudomonas aeruginosa, Klebsiella pneumoniae and Candida albicans. It was found that compounds 1.1, 1.5, 1.10, 1.31, 1.33 possessed light activity against K. pneumonia. The US National Cancer Institute (NCI) has chosen 19 compounds and screened them for ability to inhibit in 10μM concentration 60 different human tumor cell lines. The LOX IMVI cell line of melanoma appeared to be the most sensitive one, and N-(6-methylbenzo[d]thiazol-2-yl)-2-(tetrazolo[1,5-c]quinazolin-5-ylthio)acetamide (1.31) and N-(3-fluorobenzyl)-2-(tetrazolo[1,5-c]quinazolin-5-ylthio)acetamide (1.19) exhibited high growth inhibition rate, and N-(6-methoxybenzo[d]thiazol-2-yl)-2-(tetrazolo[1,5-c]quinazolin-5-ylthio)acetamide (1.32) showed lethal antitumor activity against it. The latter compound 1.32 showed the best anticancer results, also inhibiting growth of leukemia SR cell line, NCI-H460 of non-small cell lung cancer, KM12 of colon cancer and SF-295 of CNS cancer. The in silico molecular docking studies have predicted the affinity of the synthesized substances to the epidermal growth factor receptor (EGFR)Keywords
Funding Information
- Enamine Ltd
This publication has 22 references indexed in Scilit:
- Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitorsEuropean Journal of Medicinal Chemistry, 2014
- Design and Evaluation of Novel Antimicrobial and Anticancer Agents Among Tetrazolo[1,5-c]quinazoline-5-thione S-DerivativesScientia Pharmaceutica, 2013
- Synthesis of New 6-{[ω-(Dialkylamino(heterocyclyl)alkyl]thio}-3-R-2H-[1,2,4]triazino[2,3-c]quinazoline-2-ones and Evaluation of their Anticancer and Antimicrobial ActivitiesScientia Pharmaceutica, 2012
- Synthesis and biological activity of novel N-cycloalkyl-(cycloalkylaryl)-2-[(3-R-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazoline-6-yl)thio]acetamidesEuropean Journal of Medicinal Chemistry, 2011
- Synthesis, Cytotoxicity by Bioluminescence Inhibition, Antibacterial and Antifungal Activity of ([1,2,4]Triazolo[1,5‐c]quinazolin‐2‐ylthio)carboxylic Acid AmidesArchiv der Pharmazie, 2009
- Synthesis of New 2-Thio-[1,2,4]triazolo[1,5-c]quinazoline Derivatives and Its Antimicrobial ActivityChemical and Pharmaceutical Bulletin, 2009
- Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor AZD2171 and Fractionated Radiotherapy in Mouse Models of Lung CancerCancer Research, 2006
- The NCI In Vitro Anticancer Drug Discovery Screen1997
- Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screenDrug Development Research, 1995
- A definitive synthesis of 2-[(5-methyl-s-triazolo[4,3-c]quinazolin-3-yl)thio]-N-benzylacetanilide and other reactions of its precursorsCanadian Journal of Chemistry, 1984